Metagenomi Therapeutics, Inc. (MGX) stock
MGXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.63−0.05 (-7.21%)
Close on Nov 17, 2026Market cap $23.84MP/E –Yield –
Metagenomi Therapeutics price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Metagenomi Therapeutics's price to sales ratio was 2.0× on Jul 31, 2026, against 1.9× a year earlier. Over the last 3 years it ranged from 0.5× to 5.1×, with a median of 2.0×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Jul 31, 2026 | 2.0× | +0.0 |
| 2025 | Dec 31, 2025 | 2.0× | −0.5 |
| 2024 | Dec 31, 2024 | 2.5× | – |
See a number that looks wrong?